A chemically modified GLP-1 analogue of Formula I: Xaa 7 -Xaa 8 -Glu-Gly-Thr-Xaa 12 -Thr-Ser-Asp-Xaa 16 -Ser-Lys-Xaa 19 -Xaa 20 -Glu-Xaa 22 -Xaa 23 -Ala-Xaa 25 -Xaa 26 -Xaa 27 -Phe-Ile-Xaa 30 -Xaa 31 -Leu-Xaa 33 -Xaa 34 -Xaa 35 -Xaa 36 -Xaa 37 -Xaa 38, wherein Xaa 7 is L-histidine, imidazopropionyl, α-hydroxy-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, N α -acetyl-histidine, N α -formyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine, or 4-pyridylalanine; Xaa 8 is Ala, Gly, Val, Leu, Ile, Thr, Ser, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid; Xaa 12 is Phe or Leu; Xaa 16 is Val or Leu; Xaa 19 is Tyr or Gln; Xaa 20 is Leu or Met; Xaa 22 is Gly, Glu, Lys, or Aib; Xaa 23 is Gln, Glu, or Arg; Xaa 25 is Ala or Val; Xaa 26 is Val, His, Lys, or Arg; Xaa 27 is Glu, His, Leu, or Lys; Xaa 30 is Ala, Glu, Lys, or Arg; Xaa 31 is Trp, Lys, or His Xaa 33 is Val or Lys; Xaa 34 is Lys, Glu, Asn, Gly, Gln, Arg, His, or absent; Xaa 35 is Gly, Aib, or absent; Xaa 36 is Arg, Gly, Lys, or absent; Xaa 37 is Gly, Ala, Glu, Pro, Lys, Arg, or absent; and Xaa 38 is Ser, Gly, Ala, Glu, Pro, Lys, Arg, or absent; which analogue comprises a first K residue at a position corresponding to position 18 and a second K residue at a position corresponding to 22, 26, 27, 30, 31, 34, or 37 of GLP-1 (SEQ ID NO: 1), and a maximum of twelve amino acid changes as compared to GLP-1, which chemically modified GLP-1 analogue comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 2, Chem. 1, and Chem. 3, wherein -C 6 H 4 - in Chem. 2 and Chem. 3 refers to phenylene: Chem. 2: HOOC-C 6 H 4 -O-(CH 2) y -CO-* Chem. 1: HOOC-(CH 2) x -CO-* Chem. 3: R 2 -C 6 H 4 -(CH 2),-CO-*, in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, and R 2 is a group having a molar mass not higher than 150 Da; and the linker comprises wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or said chemically modified GLP-1 analogue in the form of a pharmaceutically acceptable salt, amide, or ester. Xaa 7 -Xaa 8 -Glu-Gly-Thr-Xaa 12 -Thr-Ser-Asp-Xaa 16 -Ser-Lys-Xaa 19 -Xaa 20 -Glu-Xaa 22 -Xaa 23 -Ala-Xaa 25 -Xaa 26 -Xaa 27 -Phe-Ile-Xaa 30 -Xaa 31 -Leu-Xaa 33 -Xaa 34 -Xaa 35 -Xaa 36 -Xaa 37 -Xaa 38, wherein Xaa 7 is L-histidine, imidazopropionyl, α-hydroxy-histidine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, N α -acetyl-histidine, N α -formyl-histidine, α-fluoromethyl-histidine, α-methyl-histidine, 3-pyridylalanine, 2-pyridylalanine, or 4-pyridylalanine; Xaa 8 is Ala, Gly, Val, Leu, Ile, Thr, Ser, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl) carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid; Xaa 12 is Phe or Leu; Xaa 16 is Val or Leu; Xaa 19 is Tyr or Gln; Xaa 20 is Leu or Met; Xaa 22 is Gly, Glu, Lys, or Aib; Xaa 23 is Gln, Glu, or Arg; Xaa 25 is Ala or Val; Xaa 26 is Val, His, Lys, or Arg; Xaa 27 is Glu, His, Leu, or Lys; Xaa 30 is Ala, Glu, Lys, or Arg; Xaa 31 is Trp, Lys, or His Xaa 33 is Val or Lys; Xaa 34 is Lys, Glu, Asn, Gly, Gln, Arg, His, or absent; Xaa 35 is Gly, Aib, or absent; Xaa 36 is Arg, Gly, Lys, or absent; Xaa 37 is Gly, Ala, Glu, Pro, Lys, Arg, or absent; and Xaa 38 is Ser, Gly, Ala, Glu, Pro, Lys, Arg, or absent; which analogue comprises a first K residue at a position corresponding to position 18 and a second K residue at a position corresponding to 22, 26, 27, 30, 31, 34, or 37 of GLP-1 (SEQ ID NO: 1), and a maximum of twelve amino acid changes as compared to GLP-1, which chemically modified GLP-1 analogue comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 2, Chem. 1, and Chem. 3, wherein -C 6 H 4 - in Chem. 2 and Chem. 3 refers to phenylene: Chem. 2: HOOC-C 6 H 4 -O-(CH 2) y -CO-* Chem. 1: HOOC-(CH 2) x -CO-* Chem. 3: R 2 -C 6 H 4 -(CH 2),-CO-*, in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, and R 2 is a group having a molar mass not higher than 150 Da; and the linker comprises wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or said chemically modified GLP-1 analogue in the form of a pharmaceutically acceptable salt, amide, or ester.